Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
Daniel S. Raccuia, PharmD candidate 2016
Advertisement
Daniel S. Raccuia is a 2016 PharmD candidate at University of Connecticut School of Pharmacy, Storrs, Conn.
Articles by Daniel S. Raccuia, PharmD candidate 2016
Advertisement
Latest Updated Articles
- FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting
Published: June 10th 2016 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
A1c Monitoring Could Be Delayed Up to 2 Years for Patients With Type 2 Diabetes
3
Wicked Good Cardiometabolic Chat: SGLT2is Offer Cardiorenal Benefits Beyond Diabetes
4
Why It’s Crucial to Address Insulin Resistance During Pregnancy
5
